Apotex Follows the BPCIA “Patent Dance” Again
By EsqSocial Corporation 05/11/15
The first biosimilar makers to file regulatory applications with FDA attempted to bypass all or a subset of the patent litigation provisions of the Biologics Price Competition and Innovation Act of 2009 (BPCIA). Apotex, the third biosimilar maker to...
By: Patterson Belknap Webb & Tyler LLP